News und Analysen
EQS-Adhoc: MAQUET Medical Systems AG submits squeeze-out request to Pulsion Medical Systems SE
EQS-News: Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
Chemed Corporation to Present at the 2025 RBC Global Healthcare Conference
Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the RBC Global Healthcare Conference on Wednesday, May 21, 2025, at approximately 9:30 a.m. (ET) at The
EQS-News: Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025
Savara Reports First Quarter 2025 Financial Results and Provides a Business Update
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2025 and
GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025
Regulatory News:
The Combined General Meeting of shareholders of GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and
Charles River Laboratories to Present at Bank of America Health Care Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Bank of America 2025 Health Care Conference on Wednesday, May 14th, at 8:40 a.m. PT (11:40
Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
Poxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
EQS-News: Eckert & Ziegler Starts with Earnings Growth in Q1 2025 and Confirms Full-Year Forecast
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and first quarter 2025 financial results.
“This quarter we continued to advance
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded
Acadia Healthcare Reports First Quarter 2025 Results
Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) today announced financial results for the first quarter ended March 31, 2025.
First Quarter 2025 Highlights
-
Revenue
Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and
Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the first quarter earnings call originally scheduled for 4:30p.m. Eastern on Monday, May 12 will be
Newron Announces Approval for Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-resistant Schizophrenia (TRS)
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three months ended March 31, 2025.
First Quarter 2025 Financial Results
-
Total Revenue: For the three
EQS-News: Formycon reports strong operational performance and financial results for first quarter of 2025
Lonza Announces Results of the 2025 Annual General Meeting – All Motions Proposed by Board of Directors Approved
Financial year 2024/25: Sonova achieves market share gains across all businesses and announces upcoming CEO transition
Lonza Q1 2025 Qualitative Update: Strong Performance Across All Businesses in Line with Expectations for Full-Year 2025
Puma Biotechnology Reports First Quarter Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2025. Unless otherwise stated, all comparisons are for the
Acadia Healthcare to Participate in BofA Securities Health Care Conference
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the BofA Securities 2025 Health Care Conference, May 13-15, 2025, in Las Vegas, Nevada.
In